Abstract

SummaryParallel to the increasing number of patients with obesity and metabolic syndrome, the number of bariatric procedures is rapidly growing. Gastric bypass is the surgery of choice due to its high efficiency and safety profile; however, subsequent assessment and surveillance of the excluded stomach poses considerable challenges. Gastric remnant cancer is a rare entity and only a few cases have been published in the literature. Here, we report the first case of a human epidermal growth factor receptor 2-positive gastric cancer in the excluded remnant in a 58-year-old man with a history of bariatric Roux-en‑Y gastric bypass surgery. This case highlights the challenge of cancer surveillance in the eliminated stomach and chemotherapeutic treatment after bariatric surgery. Furthermore, we address the efficacy of trastuzumab deruxtecan as a second-line therapy in HER2-positive gastric cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.